Ectropion Improvement with Topical Tazarotene in Children with Lamellar Ichthyosis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Objectives: Lamellar ichthyosis (LI) is a well-described phenotypic subtype of autosomal recessive congenital ichthyosis (ARCI). The condition typically presents at birth with collodion membrane and leads to thick, plate-like scaling of the skin throughout the body, alopecia, and prominent ocular manifestations. Ocular complications include bilateral cicatricial ectropion and lagophthalmos. These ocular complications can lead to chronic exposure keratitis and in some cases corneal ulceration and blindness. No cure for ichthyosis exists. Treatment of ocular complications in LI includes surgical correction, systemic retinoids, and a variety of topical therapies such as emollients, keratolytics, and retinoids. Methods: Five children with LI cared for at our institution were identified and included. Patient age at the start of therapy ranged from 2 weeks to 9 years. Electronic medical records were reviewed and data from pediatric dermatologist and pediatric ophthalmologist visits were obtained. Data were collected before and after treatment of daily or twice-daily 0.05% to 0.1% tazarotene cream applied to the face and eyelids. Results: All patients had improvement in the degree of ectropion, with complete resolution in two of the five patients. The two patients with lagophthalmos at the time of tazarotene initiation experienced complete resolution. No adverse effects were reported. Conclusions: Tazarotene cream appears to be effective in the management of ectropion and lagophthalmos in the setting of LI in children, even in the neonatal period.

Original languageEnglish (US)
Pages (from-to)584-589
Number of pages6
JournalPediatric Dermatology
Volume34
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Lamellar Ichthyosis
Ectropion
Ichthyosis
Retinoids
Eye Manifestations
Emollients
Pediatrics
Collodion
Keratitis
Electronic Health Records
Alopecia
Eyelids
Blindness
Therapeutics
Parturition
Skin
Membranes
tazarotene

PubMed: MeSH publication types

  • Case Reports
  • Journal Article

Cite this

Ectropion Improvement with Topical Tazarotene in Children with Lamellar Ichthyosis. / Hanson, Brooke; Becker, Lauren; Hook, Kristen P; Polcari, Ingrid C; Areaux, Raymond G; Maguiness, Sheilagh.

In: Pediatric Dermatology, Vol. 34, No. 5, 01.09.2017, p. 584-589.

Research output: Contribution to journalArticle

@article{688d73c40c394dca9d871722d8c6bc81,
title = "Ectropion Improvement with Topical Tazarotene in Children with Lamellar Ichthyosis",
abstract = "Background/Objectives: Lamellar ichthyosis (LI) is a well-described phenotypic subtype of autosomal recessive congenital ichthyosis (ARCI). The condition typically presents at birth with collodion membrane and leads to thick, plate-like scaling of the skin throughout the body, alopecia, and prominent ocular manifestations. Ocular complications include bilateral cicatricial ectropion and lagophthalmos. These ocular complications can lead to chronic exposure keratitis and in some cases corneal ulceration and blindness. No cure for ichthyosis exists. Treatment of ocular complications in LI includes surgical correction, systemic retinoids, and a variety of topical therapies such as emollients, keratolytics, and retinoids. Methods: Five children with LI cared for at our institution were identified and included. Patient age at the start of therapy ranged from 2 weeks to 9 years. Electronic medical records were reviewed and data from pediatric dermatologist and pediatric ophthalmologist visits were obtained. Data were collected before and after treatment of daily or twice-daily 0.05{\%} to 0.1{\%} tazarotene cream applied to the face and eyelids. Results: All patients had improvement in the degree of ectropion, with complete resolution in two of the five patients. The two patients with lagophthalmos at the time of tazarotene initiation experienced complete resolution. No adverse effects were reported. Conclusions: Tazarotene cream appears to be effective in the management of ectropion and lagophthalmos in the setting of LI in children, even in the neonatal period.",
author = "Brooke Hanson and Lauren Becker and Hook, {Kristen P} and Polcari, {Ingrid C} and Areaux, {Raymond G} and Sheilagh Maguiness",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/pde.13240",
language = "English (US)",
volume = "34",
pages = "584--589",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Ectropion Improvement with Topical Tazarotene in Children with Lamellar Ichthyosis

AU - Hanson, Brooke

AU - Becker, Lauren

AU - Hook, Kristen P

AU - Polcari, Ingrid C

AU - Areaux, Raymond G

AU - Maguiness, Sheilagh

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background/Objectives: Lamellar ichthyosis (LI) is a well-described phenotypic subtype of autosomal recessive congenital ichthyosis (ARCI). The condition typically presents at birth with collodion membrane and leads to thick, plate-like scaling of the skin throughout the body, alopecia, and prominent ocular manifestations. Ocular complications include bilateral cicatricial ectropion and lagophthalmos. These ocular complications can lead to chronic exposure keratitis and in some cases corneal ulceration and blindness. No cure for ichthyosis exists. Treatment of ocular complications in LI includes surgical correction, systemic retinoids, and a variety of topical therapies such as emollients, keratolytics, and retinoids. Methods: Five children with LI cared for at our institution were identified and included. Patient age at the start of therapy ranged from 2 weeks to 9 years. Electronic medical records were reviewed and data from pediatric dermatologist and pediatric ophthalmologist visits were obtained. Data were collected before and after treatment of daily or twice-daily 0.05% to 0.1% tazarotene cream applied to the face and eyelids. Results: All patients had improvement in the degree of ectropion, with complete resolution in two of the five patients. The two patients with lagophthalmos at the time of tazarotene initiation experienced complete resolution. No adverse effects were reported. Conclusions: Tazarotene cream appears to be effective in the management of ectropion and lagophthalmos in the setting of LI in children, even in the neonatal period.

AB - Background/Objectives: Lamellar ichthyosis (LI) is a well-described phenotypic subtype of autosomal recessive congenital ichthyosis (ARCI). The condition typically presents at birth with collodion membrane and leads to thick, plate-like scaling of the skin throughout the body, alopecia, and prominent ocular manifestations. Ocular complications include bilateral cicatricial ectropion and lagophthalmos. These ocular complications can lead to chronic exposure keratitis and in some cases corneal ulceration and blindness. No cure for ichthyosis exists. Treatment of ocular complications in LI includes surgical correction, systemic retinoids, and a variety of topical therapies such as emollients, keratolytics, and retinoids. Methods: Five children with LI cared for at our institution were identified and included. Patient age at the start of therapy ranged from 2 weeks to 9 years. Electronic medical records were reviewed and data from pediatric dermatologist and pediatric ophthalmologist visits were obtained. Data were collected before and after treatment of daily or twice-daily 0.05% to 0.1% tazarotene cream applied to the face and eyelids. Results: All patients had improvement in the degree of ectropion, with complete resolution in two of the five patients. The two patients with lagophthalmos at the time of tazarotene initiation experienced complete resolution. No adverse effects were reported. Conclusions: Tazarotene cream appears to be effective in the management of ectropion and lagophthalmos in the setting of LI in children, even in the neonatal period.

UR - http://www.scopus.com/inward/record.url?scp=85028977205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028977205&partnerID=8YFLogxK

U2 - 10.1111/pde.13240

DO - 10.1111/pde.13240

M3 - Article

C2 - 28815772

AN - SCOPUS:85028977205

VL - 34

SP - 584

EP - 589

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 5

ER -